Accent Capital Management LLC Decreases Holdings in Kenvue Inc. (NYSE:KVUE)

Accent Capital Management LLC reduced its position in Kenvue Inc. (NYSE:KVUE) by 43.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,859 shares of the company’s stock after selling 3,727 shares during the quarter. Accent Capital Management LLC’s holdings in Kenvue were worth $104,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Alerus Financial NA increased its position in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after buying an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC increased its holdings in shares of Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC raised its position in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its stake in Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after purchasing an additional 568 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 1.0 %

Shares of KVUE opened at $23.74 on Friday. The firm’s fifty day moving average is $22.32 and its two-hundred day moving average is $22.46. The stock has a market cap of $45.36 billion, a PE ratio of 44.78, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analysts Set New Price Targets

A number of research firms have issued reports on KVUE. Evercore ISI began coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target for the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays increased their price objective on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Thursday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.